Based on the results of the LEADER trial, where would you likely position liraglutide in the framework of individualized ADA/EASD guidelines?

Based on the results of the LEADER trial, where would you likely position liraglutide in the framework of individualized ADA/EASD guidelines?

Based on the results of the LEADER trial, where would you likely position liraglutide in the framework of individualized ADA/EASD guidelines?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Juan Frias, FACE, MD

Juan Frias, FACE, MD

Clinical Assistant Professor of Medicine
University of California
San Diego, California
Chief Medical Officer
National Research Institute
Los Angeles, California